$250,000 of BRIGHTSPRING HEALTH SERVICES lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Long-term care pharmacy and other pharmacy issues HR 5130/S 3159, IRA implementation issues included), Medicare payment rules including hospice, home health and physician fee schedule (HR 5142 included), home infusion fix, Medicaid regulations, workforce development Long-term care pharmacy fix, IRA implementation"
You can find more data on corporate lobbying on Quiver Quantitative.
BTSG Insider Trading Activity
BTSG insiders have traded $BTSG stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $BTSG stock by insiders over the last 6 months:
- GROUP PARTNERSHIP L.P. KKR has made 0 purchases and 2 sales selling 34,460,000 shares for an estimated $1,231,936,705.
- PHOENIX AGGREGATOR L.P. KKR has made 0 purchases and 2 sales selling 34,460,000 shares for an estimated $1,231,936,705.
- JON B ROUSSEAU (See Remarks) has made 0 purchases and 2 sales selling 455,000 shares for an estimated $15,816,770.
- LISA A NALLEY (See Remarks) has made 0 purchases and 2 sales selling 50,000 shares for an estimated $1,810,140.
- JENNIFER A PHIPPS (Chief Financial Officer) sold 35,000 shares for an estimated $1,440,250
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BTSG Hedge Fund Activity
We have seen 192 institutional investors add shares of BTSG stock to their portfolio, and 128 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KOHLBERG KRAVIS ROBERTS & CO. L.P. removed 15,154,305 shares (-19.7%) from their portfolio in Q4 2025, for an estimated $567,528,722
- BLACKROCK, INC. added 9,372,929 shares (+123.1%) to their portfolio in Q4 2025, for an estimated $351,016,191
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 3,958,691 shares (-78.7%) from their portfolio in Q4 2025, for an estimated $148,252,977
- VANGUARD GROUP INC added 2,928,953 shares (+30.5%) to their portfolio in Q4 2025, for an estimated $109,689,289
- FMR LLC removed 2,325,097 shares (-9.3%) from their portfolio in Q4 2025, for an estimated $87,074,882
- ROYAL BANK OF CANADA removed 2,198,147 shares (-99.6%) from their portfolio in Q4 2025, for an estimated $82,320,605
- STATE STREET CORP added 2,011,095 shares (+99.5%) to their portfolio in Q4 2025, for an estimated $75,315,507
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BTSG Analyst Ratings
Wall Street analysts have issued reports on $BTSG in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wells Fargo issued a "Overweight" rating on 01/07/2026
- BTIG issued a "Buy" rating on 12/23/2025
- Stephens & Co. issued a "Overweight" rating on 12/11/2025
- William Blair issued a "Outperform" rating on 12/08/2025
- BMO Capital issued a "Outperform" rating on 11/13/2025
- Mizuho issued a "Outperform" rating on 10/17/2025
- Morgan Stanley issued a "Overweight" rating on 10/14/2025
To track analyst ratings and price targets for BTSG, check out Quiver Quantitative's $BTSG forecast page.
BTSG Price Targets
Multiple analysts have issued price targets for $BTSG recently. We have seen 9 analysts offer price targets for $BTSG in the last 6 months, with a median target of $45.0.
Here are some recent targets:
- Erin Wright from Morgan Stanley set a target price of $48.0 on 03/04/2026
- Ann Hynes from Mizuho set a target price of $50.0 on 03/03/2026
- Stephen Baxter from Wells Fargo set a target price of $50.0 on 03/02/2026
- David Larsen from BTIG set a target price of $55.0 on 03/02/2026
- Matthew Gillmor from Keybanc set a target price of $45.0 on 12/12/2025
- Dean Sublett from Stephens & Co. set a target price of $44.0 on 12/11/2025
- Joanna Gajuk from B of A Securities set a target price of $41.0 on 12/09/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
